The company's GS1-144 tablets are a Class I new chemical drug. It is a small molecule NK3R antagonist independently developed by the company. There is no NK3R target drug on the market in China. As a non-hormonal oral therapy for menopausal vasomotor syndrome, this product can provide patients with better treatment options. During the reporting period, GS1-144 tablets launched Phase I clinical trials in China and Australia.